Gå til hovedindhold

Om Acarix AS

Acarix is a Danish/Swedish commercial stage medical device company specializing in non-invasive, acoustic rule-out of Coronary Artery Disease (CAD).

Acarix was established in 2009 as a spin-out company from Coloplast A/S. Since 2010 key investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have financed the development of the company and supported it towards market introduction.

Acarix received CE-approval in 2015 for its CADScor®System, for easy rule-out of coronary artery disease, which is now actively marketed in the Northern European markets.

Since December 2016 the company has been listed on Nasdaq First North Premier in Stockholm.

More info at www.acarix.com